Non-Chemotherapy Combinations in CLL

Program Overview

CLL Drug Development Timeline

mAbs Approved for CLL

BCR Signaling in CLL

RESONATE: Ibrutinib vs Ofatumumab in Patients With R/R CLL

Ibrutinib in Patients With R/R Del(17p) CLL

Ibrutinib Monotherapy in Treatment-Naive CLL: 5-Year Outcomes

Ibrutinib + Rituximab vs Ibrutinib Monotherapy in TN and R/R CLL

Idelalisib + Rituximab vs Placebo + Rituximab in R/R CLL

Idelalisib + Rituximab in Patients With R/R Del(17p) CLL

Venetoclax

Venetoclax Monotherapy in R/R Del(17p) CLL

Venetoclax + Rituximab in R/R CLL: MRD Negativity After Treatment Discontinuation

MURANO: Venetoclax + Rituximab vs BR in R/R CLL

VenR vs BR in Patients by Del(17p) and TP53 and IGHV Mutation Status

PB MRD Negativity With VenR vs BR by Del(17p) and TP535 and IGHV Mutation Status

Rationale for Novel Agents/Combinations in Development: Potential Benefits

Novel Agents in Development: Acalabrutinib and Ublituximab

BTK Inhibitor Acalabrutinib Monotherapy or in Combination With Obinutuzumab

GENUINE: Ublituximab + Ibrutinib in Patients With High Risk CLL

Rationale for Combining BTK Inhibitor and BCL2 Inhibitor

CLARITY: Venetoclax + Ibrutinib in R/R CLL

CAPTIVATE: Ibrutinib + Venetoclax in TN CLL

Combination Approaches of Novel Agents

Venetoclax + Obinutuzumab in TN CLL

CLL14: Venetoclax + Obinutuzumab in Patients With TN CLL and Coexisting Medical Conditions

Triple Therapy: Obinutuzumab + Ibrutinib + Venetoclax in TN CLL

New Targets in R/R CLL

Ongoing Clinical Trials in CLL: Doublet Therapy

Ongoing Clinical Trials in CLL: Triplet Therapy

Take-Home Messages

Abbreviations

Abbreviations (cont)

Abbreviations (cont)